

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A




FIG. 2B




FIG. 3

4/31




FIG. 4




FIG. 5A

5/31




FIG. 5B




FIG. 6

6/31




FIG. 7A




FIG. 7B

7/31




FIG. 8A




FIG. 8B

8/31




FIG. 9






FIG. 10


9/31



- HBS
- INX-6295 (2 mg/kg)
- ▼— INX-6295 (5 mg/kg)
- ▽— AS4200/INX-6295 (2 mg/kg)
- AS4200/INX-6295 (5 mg/kg)
- AS4204/INX-6295 (2 mg/kg)
- ◆— AS4204/INX-6295 (5 mg/kg)
- ◇— INX-6300 (5 mg/kg)
- ▲— AS4200/INX-6300 (5 mg/kg)
- △— AS4204/INX-6300 (5 mg/kg)

FIG. 11A

10/31



- ◆ HBS
- 2 mg/kg free c-myc
- 2 mg/kg c-myc/AS4200
- ▽ 2 mg/kg c-myc/DODAC: DOPE
- 10 mg/kg free c-myc
- 10 mg/kg c-myc/AS4200
- △ 10 mg/kg c-myc/AS4204

FIG. 11B




FIG. 12




FIG. 13

13/31

INCREASE IN TUMOUR FOLD (mm)

—○— Free 15 mer-10 mg/kg (LR-3280)
—□— Free (15 mer 4G control)-10 mg/kg (LR-4420)

* Injection Day

DAYS AFTER IMPLANTATION

Days After Implantation	Free 15 mer-10 mg/kg (LR-3280) (mm)	Free (15 mer 4G control)-10 mg/kg (LR-4420) (mm)
9	1.2	1.2
11	4.2	3.0
13	4.8	3.5
15	7.5	5.2
17	11.8	7.8
19	14.2	9.2
21	17.2	13.8

FIG. 14

Treatment Group	Increase in Tumour Volume (-Fold) $(L \times W \times H) \times 0.54$
HBS	~27.5
Free Dox (2) mg/kg	~27.5
AS4200 15 mg/kg	~14.5
L4200 (Dox); (2) mg/kg	~20.5
AS4200 (Dox); 15 (2) mg/kg	~8.5
L4200 (Dox); (10) mg/kg	~6.0
AS4200 (Dox); 15 (10) mg/kg	~9.5

FIG. 15

FIG. 15




FIG. 16




FIG. 17

201000-22498001




FIG. 18A




FIG. 18B

16/31




FIG. 19A




FIG. 19B




FIG. 20




FIG. 21




FIG. 22A




FIG. 22B




FIG. 23A

19/31




FIG. 23B




FIG. 23C

20/21




FIG. 24A




FIG. 24B




FIG. 24C




FIG. 25




FIG. 26A




FIG. 26B

22/31




FIG. 26C




FIG. 27




FIG. 28A




FIG. 28B




FIG. 28C




FIG. 28D

25/31




FIG. 29A




FIG. 29B

26/31




FIG. 29C




FIG. 29D

27/31




FIG. 30A




FIG. 30B

2010E0-22498001

28/31




FIG. 30C




FIG. 30D

2010E0-2498001

29/31




FIG. 31A




FIG. 31B

10086477-030102

30/31




FIG. 32A




FIG. 32B




FIG. 33